The short version of hexenoyl cap fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-25. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
=== Southeast Asia === Tofu is called tauhu in Malaysia and Singapore as well as tahu in Indonesia both from Hokkien tāu-hū; it is also known as taufu in Malaysia from Cantonese. Indonesia, Thailand, Malaysia, and the Philippines are major producers of tofu and have plants in many municipalities.
Meyer even criticized Hutchinson publicly, prompting a meeting between the three men and team owner August Busch Jr., in which Hutchinson appealed to the owner to "Let me alone to do my job." "That thing with Mizell in Brooklyn, I just wanted to get him over a hump," Hutchinson later explained. Through July 27, Mizell had a 5.32 ERA, but his control started to improve in the middle of the year. Called on for a start on July 29, he held the Pirates to two hits in a 4–0 shutout victory. Thereafter, most of his appearances would be starts. With the second-place Cardinals trailing the NL-leading Milwaukee Braves on August 18, Mizell threw a four-hit shutout, helping the Cardinals sweep a doubleheader and remain in the pennant race. His ERA after July 27 was 2.54. In 33 games (21 starts), he had an 8–10 record, a 3.74 ERA, 87 strikeouts, and 51 walks in 149+1⁄3 innings. Over the 1957–58 offseason, Mizell practiced throwing with a steel ball. He arrived early to 1958 spring training, claiming to have lost 12 pounds from the previous spring. He had a 3–6 record entering June 21, but from that date through July 12, he won four straight games. On June 25, though he walked five batters, he allowed just three hits and one unearned run in a 3–1 victory over the Pirates. Then, on July 12, he threw a shutout in a 2–0 win over the Pirates. He had a pitching duel against Joe Nuxhall of Cincinnati in the first game of a doubleheader on September 1; Mizell prevailed 1–0, setting an NL record for most walks in a shutout with nine.
=== Well-being measurement === Different ways of measuring well-being reveal different contributing factors. The correlation between two of these, life satisfaction and happiness, in the World Values Survey (1981–2005) is only 0.47. These are different, but related concepts which are used interchangeably outside of academia. Typically, life satisfaction, or evaluative wellbeing is measured with Cantril's self-anchoring ladder, a questionnaire where wellbeing is rated on a scale from 1–10. Happiness or hedonic/Affective well-being measurement is measured with the positive and negative affect schedule (PANAS), a more complex scale.
Sources: en.wikipedia.org
==== Steroids ==== The hypothalamus contains neurons that react strongly to steroids and glucocorticoids (the steroid hormones of the adrenal gland, released in response to ACTH). It also contains specialized glucose-sensitive neurons (in the arcuate nucleus and ventromedial hypothalamus), which are important for appetite. The preoptic area contains thermosensitive neurons; these are important for TRH secretion.
== Benedictine life == Born in 1835 at Bouzemont, France, Dom Joseph Pothier was ordained a priest in the diocese of Saint-Dié in 1858, before immediately joining St Peter's Abbey, Solesmes under Abbot Dom Prosper Guéranger. By founding, in the then derelict priory of Solesmes, the first new abbey of the Order of Saint Benedict in France, Dom Guéranger had re-established monastic life in the country after it had been wiped out by the French Revolution. Pothier later was made subprior (1862-1863 and 1866-1893) of Solesmes, then claustral prior (1893-1894) of St Martin's Abbey, Ligugé, also a former deserted priory which had been resettled by Solesmes. In 1895 he became superior of the colony of monks from Ligugé sent to repopulate the monastery of St Wandrille (Fontenelle), an ancient and abandoned Benedictine abbey - also suppressed during the French Revolution - in Saint-Wandrille-Rançon, Normandy. Pope Leo XIII having restored the abbatial title of Fontenelle specially for him, Dom Pothier was eventually raised to the dignity of Abbot of St Wandrille's Abbey (installed on 24 July 1898) - becoming the first abbot of the monastery since the French Revolution and its first regular abbot since the 16th century. Cardinal Guillaume Sourrieu, Archbishop of Rouen and Primate of Normandy, assisted by the abbots of Solesmes and Ligugé as co-consecrators, conferred the abbatial blessing upon him on 29 September 1898, in the presence of three other prelates and 150 priests.
As of this edit, this article uses content from "2.A.37 The Monovalent Cation:Proton Antiporter-2 (CPA2) Family", which is licensed in a way that permits reuse under the Creative Commons Attribution-ShareAlike 3.0 Unported License, but not under the GFDL. All relevant terms must be followed.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.